NAD+ Research: Key Published Studies & Findings

A literature review of NAD+ biology research spanning aging, metabolism, neurodegeneration, and cellular repair

Research Overview

NAD+ research has undergone an explosion of activity since the early 2000s, driven by the discovery that NAD+-dependent sirtuins mediate caloric restriction effects (Guarente, Sinclair) and the realization that NAD+ levels decline substantially with age. The field now encompasses thousands of publications across aging biology, metabolic disease, neurodegeneration, and DNA repair.

Aging Biology and Senescence

The connection between NAD+ and aging was established through landmark studies showing NAD+ levels decline 40-60% with age across multiple tissues in animal models, restoring NAD+ levels in aged mice altered mitochondrial function and physical endurance (Gomes et al., 2013), CD38 was identified as the primary driver of age-related NAD+ decline (Camacho-Pereira et al., 2016), and sirtuin activation through NAD+ repletion partially reversed age-related physiological decline in multiple organ systems.

Metabolic Disease Research

NAD+ metabolism is deeply connected to metabolic health. Published studies demonstrate NAD+ repletion via precursors (NMN, NR) altered insulin sensitivity and glucose tolerance in diet-induced obesity models, NAMPT (the rate-limiting NAD+ biosynthesis enzyme) is downregulated in diabetic and obese tissues, hepatic NAD+ depletion contributes to fatty liver disease progression, and tissue-specific NAD+ manipulation affects systemic metabolic homeostasis through inter-organ signaling.

Neurodegeneration Research

The brain is particularly sensitive to NAD+ depletion due to its high metabolic demand. Published findings include NAD+ decline in neurodegenerative disease models (Alzheimer’s, Parkinson’s), SIRT1/SIRT3 activation via NAD+ providing neuroprotective effects, PARP hyperactivation in neurodegeneration causing NAD+ depletion, and NAD+ repletion improving cognitive function and reducing neuroinflammation in aged animal models.

DNA Repair

NAD+’s role as a PARP substrate directly links it to genomic maintenance. Research shows that NAD+ depletion compromises DNA repair capacity (impaired PARP function), xeroderma pigmentosum and Cockayne syndrome models show NAD+ pathway disruption, PARP inhibitor combinations with NAD+ precursors show complex interactions in preclinical models, and NAD+ repletion can rescue DNA repair capacity in NAD+-depleted cells.

Human Clinical Studies

NAD+ precursor supplementation has reached human trials. Published clinical data includes NR supplementation safely elevated NAD+ levels in healthy volunteers (Trammell et al., 2016), NMN supplementation improved myocyte insulin sensitivity in older women (Yoshino et al., 2021), multiple safety studies confirmed tolerability of NAD+ precursors, and ongoing trials examining cognitive, metabolic, and cardiovascular endpoints.

Area	Evidence Level	Key Findings
Aging biology	Extensive preclinical + early clinical	NAD+ decline drives multi-system aging
Metabolic disease	Robust preclinical + clinical trials	Altered insulin sensitivity, liver protection
Neurodegeneration	Multiple preclinical models	Neuroprotection, cognitive-marker changes
DNA repair	Mechanistic + preclinical	PARP-dependent genomic maintenance
Exercise/myocyte tissue	Preclinical + emerging clinical	Mitochondrial function, endurance

Disclaimer: This literature review summarizes published research for educational purposes. ANKR Lab products are intended for research use only.